Aclaris Therapeutics - ACRS Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $26.00 to $50.00. On average, they expect the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 113.4% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.

Aclaris Therapeutics' stock was trading at $14.54 at the start of the year. Since then, ACRS shares have increased by 22.5% and is now trading at $17.81.
View the best growth stocks for 2022 here.

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our ACRS earnings forecast.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.05. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.14% and a negative net margin of 1,355.98%.

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Silverarc Capital Management LLC (0.81%), Assenagon Asset Management S.A. (0.44%), Integral Health Asset Management LLC (0.43%), Swiss National Bank (0.15%), Requisite Capital Management LLC (0.07%) and State Board of Administration of Florida Retirement System (0.03%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRS stock can currently be purchased for approximately $17.81.

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $1.19 billion and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

Aclaris Therapeutics employs 72 workers across the globe.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.